BRISTOL-MYERS SQUIBB COMPANY Cost of Revenue
BRISTOL-MYERS SQUIBB COMPANY (BMY) reported Cost of Revenue of $3.73 billion for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Expense Statement
us-gaap:CostOfGoodsAndServicesSold · last filed 2026-07-30
- BRISTOL-MYERS SQUIBB COMPANY cost of goods and services sold for the quarter ending 2026-06-30 was $3.73B, a 10.50% increase year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY cost of goods and services sold for the quarter ending 2026-03-31 was $3.42B, a 12.79% increase year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY cost of goods and services sold for the quarter ending 2025-12-31 was $4.10B, a 14.86% decline year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY cost of goods and services sold for the quarter ending 2025-09-30 was $3.44B, a 16.17% increase year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY cost of goods and services sold for fiscal 2025 was $13.94B, a 0.23% decline from fiscal 2024.
- BRISTOL-MYERS SQUIBB COMPANY cost of goods and services sold for fiscal 2024 was $13.97B, a 30.63% increase from fiscal 2023.
- BRISTOL-MYERS SQUIBB COMPANY cost of goods and services sold for fiscal 2023 was $10.69B, a 5.48% increase from fiscal 2022.
- BRISTOL-MYERS SQUIBB COMPANY cost of goods and services sold for fiscal 2022 was $10.14B, a 1.98% increase from fiscal 2021.
| Period end | Cost of Goods and Services Sold 3 month | Cost of Goods and Services Sold 3 month as first filed | Cost of Goods and Services Sold 6 month | Cost of Goods and Services Sold 6 month as first filed | Cost of Goods and Services Sold 9 month | Cost of Goods and Services Sold 9 month as first filed | Cost of Goods and Services Sold 12 month | Cost of Goods and Services Sold 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $3.73B 10-Q · filed 2026-07-30 | $7.15B 10-Q · filed 2026-07-30 | $11.24B derived: sum of 3 quarters · filed 2026-07-30 | $14.68B derived: sum of 4 quarters · filed 2026-07-30 | ||||
| 2026-03-31 | $3.42B 10-Q · filed 2026-04-30 | $7.52B derived: sum of 2 quarters · filed 2026-04-30 | $10.95B derived: sum of 3 quarters · filed 2026-04-30 | $14.32B derived: sum of 4 quarters · filed 2026-07-30 | ||||
| 2025-12-31 | $4.10B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $7.53B derived: sum of 2 quarters · filed 2026-02-11 | $10.90B derived: sum of 3 quarters · filed 2026-07-30 | $13.94B 10-K · filed 2026-02-11 | ||||
| 2025-09-30 | $3.44B 10-Q · filed 2025-10-30 | $6.81B derived: sum of 2 quarters · filed 2026-07-30 | $9.84B 10-Q · filed 2025-10-30 | $14.65B derived: sum of 4 quarters · filed 2026-07-30 | ||||
| 2025-06-30 | $3.37B 10-Q · filed 2026-07-30 | $6.40B 10-Q · filed 2026-07-30 | $11.22B derived: sum of 3 quarters · filed 2026-07-30 | $14.17B derived: sum of 4 quarters · filed 2026-07-30 | ||||
| 2025-03-31 | $3.03B 10-Q · filed 2026-04-30 | $7.84B derived: sum of 2 quarters · filed 2026-04-30 | $10.80B derived: sum of 3 quarters · filed 2026-04-30 | $14.07B derived: sum of 4 quarters · filed 2026-04-30 | ||||
| 2024-12-31 | $4.81B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $7.77B derived: sum of 2 quarters · filed 2026-02-11 | $11.04B derived: sum of 3 quarters · filed 2026-02-11 | $13.97B 10-K · filed 2026-02-11 | ||||
| 2024-09-30 | $2.96B 10-Q · filed 2025-10-30 | $6.22B derived: sum of 2 quarters · filed 2025-10-30 | $9.16B 10-Q · filed 2025-10-30 | $11.90B derived: sum of 4 quarters · filed 2026-02-11 | ||||
| 2024-06-30 | $3.27B 10-Q · filed 2025-07-31 | $6.20B 10-Q · filed 2025-07-31 | $8.94B derived: sum of 3 quarters · filed 2026-02-11 | $11.45B derived: sum of 4 quarters · filed 2026-02-11 | ||||
| 2024-03-31 | $2.93B 10-Q · filed 2025-04-24 | $5.68B derived: sum of 2 quarters · filed 2026-02-11 | $8.18B derived: sum of 3 quarters · filed 2026-02-11 | $11.06B derived: sum of 4 quarters · filed 2026-02-11 | ||||
| 2023-12-31 | $2.75B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $5.25B derived: sum of 2 quarters · filed 2026-02-11 | $8.13B derived: sum of 3 quarters · filed 2026-02-11 | $10.69B 10-K · filed 2026-02-11 | ||||
| 2023-09-30 | $2.51B 10-Q · filed 2024-10-31 | $5.38B derived: sum of 2 quarters · filed 2024-10-31 | $7.95B 10-Q · filed 2024-10-31 | $10.54B derived: sum of 4 quarters · filed 2025-02-12 | ||||
| 2023-06-30 | $2.88B 10-Q · filed 2024-07-26 | $5.44B 10-Q · filed 2024-07-26 | $8.04B derived: sum of 3 quarters · filed 2025-02-12 | $10.39B derived: sum of 4 quarters · filed 2025-02-12 | ||||
| 2023-03-31 | $2.57B 10-Q · filed 2024-04-25 | $5.16B derived: sum of 2 quarters · filed 2025-02-12 | $7.51B derived: sum of 3 quarters · filed 2025-02-12 | $10.23B derived: sum of 4 quarters · filed 2025-02-12 | ||||
| 2022-12-31 | $2.59B derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-12 | $4.95B derived: sum of 2 quarters · filed 2025-02-12 | $7.67B derived: sum of 3 quarters · filed 2025-02-12 | $10.14B 10-K · filed 2025-02-12 | ||||
| 2022-09-30 | $2.35B 10-Q · filed 2023-10-26 | $5.07B derived: sum of 2 quarters · filed 2023-10-26 | $7.54B 10-Q · filed 2023-10-26 | $9.90B derived: sum of 4 quarters · filed 2024-02-13 | ||||
| 2022-06-30 | $2.72B 10-Q · filed 2023-07-27 | $5.19B 10-Q · filed 2023-07-27 | $7.55B derived: sum of 3 quarters · filed 2024-02-13 | $9.84B derived: sum of 4 quarters · filed 2024-02-13 | ||||
| 2022-03-31 | $2.47B 10-Q · filed 2023-04-27 | $4.83B derived: sum of 2 quarters · filed 2024-02-13 | $7.12B derived: sum of 3 quarters · filed 2024-02-13 | $9.57B derived: sum of 4 quarters · filed 2024-02-13 | ||||
| 2021-12-31 | $2.36B derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-13 | $4.65B derived: sum of 2 quarters · filed 2024-02-13 | $7.10B derived: sum of 3 quarters · filed 2024-02-13 | $9.94B 10-K · filed 2024-02-13 | ||||
| 2021-09-30 | $2.29B 10-Q · filed 2022-10-26 | $4.74B derived: sum of 2 quarters · filed 2022-10-26 | $7.58B 10-Q · filed 2022-10-26 | $10.49B derived: sum of 4 quarters · filed 2023-02-14 | ||||
| 2021-06-30 | $2.45B 10-Q · filed 2022-07-27 | $5.29B 10-Q · filed 2022-07-27 | $8.20B derived: sum of 3 quarters · filed 2023-02-14 | $10.71B derived: sum of 4 quarters · filed 2023-02-14 | ||||
| 2021-03-31 | $2.84B 10-Q · filed 2022-04-29 | $5.75B derived: sum of 2 quarters · filed 2023-02-14 | $8.25B derived: sum of 3 quarters · filed 2023-02-14 | $10.95B derived: sum of 4 quarters · filed 2023-02-14 | ||||
| 2020-12-31 | $2.91B derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-14 | $5.41B derived: sum of 2 quarters · filed 2023-02-14 | $8.11B derived: sum of 3 quarters · filed 2023-02-14 | $11.77B 10-K · filed 2023-02-14 | ||||
| 2020-09-30 | $2.50B 10-Q · filed 2021-10-27 | $5.20B derived: sum of 2 quarters · filed 2021-10-27 | $8.86B 10-Q · filed 2021-10-27 | $11.36B derived: sum of 4 quarters · filed 2022-02-09 | ||||
| 2020-06-30 | $2.70B 10-Q · filed 2021-07-28 | $6.36B 10-Q · filed 2021-07-28 | $8.85B derived: sum of 3 quarters · filed 2022-02-09 | $10.64B derived: sum of 4 quarters · filed 2022-02-09 | ||||
| 2020-03-31 | $3.66B 10-Q · filed 2021-04-29 | $6.15B derived: sum of 2 quarters · filed 2022-02-09 | $7.94B derived: sum of 3 quarters · filed 2022-02-09 | $9.92B derived: sum of 4 quarters · filed 2022-02-09 | ||||
| 2019-12-31 | $2.49B derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-09 | $4.28B derived: sum of 2 quarters · filed 2022-02-09 | $6.25B derived: sum of 3 quarters · filed 2022-02-09 | $8.08B 10-K · filed 2022-02-09 | ||||
| 2019-09-30 | $1.79B 10-Q · filed 2020-11-05 | $1.81B 10-Q · filed 2019-10-31 | $3.76B derived: sum of 2 quarters · filed 2020-11-05 | $5.59B 10-Q · filed 2020-11-05 | $5.65B 10-Q · filed 2019-10-31 | $7.20B derived: sum of 4 quarters · filed 2021-02-10 | ||
| 2019-06-30 | $1.97B 10-Q · filed 2020-08-06 | $1.99B 10-Q · filed 2019-07-25 | $3.80B 10-Q · filed 2020-08-06 | $3.84B 10-Q · filed 2019-07-25 | $5.41B derived: sum of 3 quarters · filed 2021-02-10 | $7.05B derived: sum of 4 quarters · filed 2021-02-10 | ||
| 2019-03-31 | $1.82B 10-Q · filed 2020-05-07 | $1.84B 10-Q · filed 2019-04-25 | $3.43B derived: sum of 2 quarters · filed 2021-02-10 | $5.08B derived: sum of 3 quarters · filed 2021-02-10 | $6.71B derived: sum of 4 quarters · filed 2021-02-10 | |||
| 2018-12-31 | $1.61B derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-10 | $3.26B derived: sum of 2 quarters · filed 2021-02-10 | $4.88B derived: sum of 3 quarters · filed 2021-02-10 | $6.47B 10-K · filed 2021-02-10 | $6.55B 10-K · filed 2019-02-25 | |||
| 2018-09-30 | $1.65B 10-Q · filed 2019-10-31 | $3.27B derived: sum of 2 quarters · filed 2019-10-31 | $4.86B 10-Q · filed 2019-10-31 | |||||
| 2018-06-30 | $1.63B 10-Q · filed 2019-07-25 | $3.21B 10-Q · filed 2019-07-25 | ||||||
| 2018-03-31 | $1.58B 10-Q · filed 2019-04-25 | |||||||
| 2017-12-31 | $6.01B 10-K · filed 2020-02-24 | $6.09B 10-K · filed 2019-02-25 | ||||||
| 2016-12-31 | $4.97B 10-K · filed 2019-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |